Alternate Day versus Once Daily Atorvastatin for Primary Prevention of (CHD) in Naïve Patients of Dyslipidemia | Zendy

Canna Ghia | Zendy; Archana Sushil Panda | Zendy; Linesh R Khobragade | Zendy; Rajesh Kumar Jha | Zendy; Gautam Rambhad | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Alternate Day versus Once Daily Atorvastatin for Primary Prevention of (CHD) in Naïve Patients of Dyslipidemia

Author(s) -

Canna Ghia,

Archana Sushil Panda,

Linesh R Khobragade,

Rajesh Kumar Jha,

Gautam Rambhad

Publication year - 2014

Publication title -

journal of clinical and diagnostic research

Language(s) - English

Resource type - Journals

eISSN - 2249-782X

pISSN - 0973-709X

DOI - 10.7860/jcdr/2014/7359.4096

Subject(s) - atorvastatin , dyslipidemia , medicine , ldl cholesterol , hmg coa reductase , reductase , very low density lipoprotein , lipoprotein , low density lipoprotein , cholesterol , endocrinology , pharmacology , chemistry , biochemistry , enzyme , obesity

Statins (or HMG-CoA reductase inhibitors) have become drug of choice for raised Low-Density Lipoprotein Cholesterol (LDL-C) in treating. Of these, Atorvastatin, because of its prolonged 3-hydroxy-3-methylglutaryl-coenzyme A (HMG CoA) reductase inhibition has been considered for alternate day therapy in primary prevention of (CHD).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research